ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.

Michael Willis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.